Orthologic amends PMA (pre-market approval) for spinal fusion product:
This article was originally published in Clinica
OrthoLogic has submitted its amended premarket approval (PMA) supplement for its spinal fusion product, the SpinaLogic-1000. This is the second amendment made by the Tempe, Arizona-based company since the original supplement was submitted to the FDA in August last year (see Clinica No 823, p 17). SpinaLogic-1000, which uses OrthoLogic's combined magnetic field technology, is designed to act as an adjunct to spinal fusion surgery and to help stimulate bone fusion.
You may also be interested in...
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.